A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

An investigational antihypertensive agent that inhibits the enzyme involved in aldosterone production, called MLS-101, significantly reduces blood pressure in patients with uncontrolled and resistant ...

Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...

PHILADELPHIA -- An oral investigational aldosterone synthase inhibitor (ASI) cut albuminuria by nearly 40% in people in chronic kidney disease (CKD) in a phase II trial. The 10-mg dose of ASI BI ...

A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal [1] ...

Current screening guidelines may not capture all cases of hyperaldosteronism among patients with ESKD. Hyperaldosteronism occurs in a higher proportion of patients with end-stage kidney disease (ESKD) ...

Type 2 diabetes (T2D) incidence continues to rise among African Americans (AAs). However, it has been observed to plateau among non-Hispanic whites (NHWs). Moreover, T2D-associated mortality and ...

Salivary free aldosterone awakening response (AldAR) differed in men with coronary heart disease and essential hypertension compared with healthy control individuals with normotension. Higher AldAR ...

Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists, particularly the most recently approved agent finerenone, should play a ...